<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02046733</url>
  </required_header>
  <id_info>
    <org_study_id>ETOP/IFCT 4-12</org_study_id>
    <secondary_id>2013-002609-78</secondary_id>
    <secondary_id>CA184-310</secondary_id>
    <secondary_id>SNCTP000000166</secondary_id>
    <nct_id>NCT02046733</nct_id>
  </id_info>
  <brief_title>Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease</brief_title>
  <acronym>STIMULI</acronym>
  <official_title>A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Thoracic Oncology Platform</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig Center for Cancer Research of Lausanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Frontier Science Foundation, Hellas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Thoracic Oncology Platform</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the fact that the majority of the patients with limited disease SCLC will respond
      very well to the standard treatment, a great proportion will relapse within 12 - 24 months.

      Several studies in patients with lung cancer suggested a possible favourable association
      between the increased presence of immunologically active cells in the tumour and survival.
      Nivolumab and ipilimumab are proteins, which help your immune system to attack and destroy
      cancer cells by your immune cells. Early clinical trials with nivolumab and ipilimumab have
      shown activity in a broad range of cancers, including SCLC.

      The aim of the current study is to investigate the efficacy (how well the treatment works)
      and tolerability (how severe the side effects are) of the standard treatment (chemotherapy
      and radiotherapy) alone, compared with the standard treatment followed by nivolumab and
      ipilimumab in patients with limited SCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the time of diagnosis, 30% of patients with small cell lung carcinoma (SCLC) will have
      limited stage disease, now called stage I-IIIB (IASLC). The outcome of limited disease SCLC
      is still poor, with a median survival of 16 to 24 months with current forms of treatment and
      only 15-25% long term survivors.

      Combining chemotherapy and thoracic radiotherapy is the standard treatment approach in
      limited-stage SCLC with a combination of platinum compounds (cis- or carboplatin) and
      etoposide and cisplatin (PE) as the backbone regimen. Concurrent chemo-radiotherapy is
      superior to sequential treatment and early thoracic irradiation starting with first or second
      cycle of chemotherapy appears beneficial. Hyperfractionated accelerated radiotherapy has been
      shown to be more efficacious than radiotherapy given in a long overall treatment time.
      However, availability and routine-use of hyperfractionated radiotherapy remains a matter of
      debate. Therefore, in this trial, both radiotherapy schedules of accelerated twice-daily
      administration or once-daily radiotherapy are accepted. The choice of schedule is a
      stratification factor for randomisation.

      The adaptive immune response is triggered via effector T-cells, antigen-presenting cells
      (APCs) and co-stimulatory signals mediated by T cell receptors such as CD28. The interplay of
      these signals results in the activation and clonal proliferation of T cells.

      T-cell proliferation is tightly regulated in order to avoid autoimmunity. The balance between
      co-stimulatory signals mediated by CD28 and co-inhibitory signals via so called immune
      checkpoint receptors is crucial for the maintenance of self-tolerance and to protect tissues
      from damage during normal immune response. After activation, T-cells express the immune
      checkpoint receptors cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death
      protein 1 (PD-1).

      CTLA-4- and PD-1 expressing T-cells play a critical role in maintaining self-tolerance but
      are also responsible for non-responsiveness to tumour antigens. Cancer cells escape from
      im-mune surveillance by expressing immune checkpoint receptors. The goal of immune
      check-point inhibitor therapies is not to activate the immune system to attack particular
      targets on tumour cells, but rather to remove inhibitory pathways that block effective
      antitumour T cell responses.

      Ipilimumab is a monoclonal antibody that binds to CTLA-4 and inhibits the interactions with
      the ligands B7.1 and B7.2, Nivolumab is a monoclonal antibody that targets PD-1. Engagement
      of PD-1 by its natural ligands, PD-L1 and PD-L2, results in an inhibition of T cell
      proliferation, survival and cyto-kine secretion. Nivolumab abrogates this interaction between
      PD-1 and its ligands.

      The two antibodies, nivolumab and ipilimumab, do not only target different immune cell
      receptors, they also regulate distinct inhibitory pathways and have therefore non-overlapping
      mechanisms of action. Anti-CTLA-4 therapies seem to drive T-cells into tumours, resulting in
      an increased number of intratumour T-cells and a concomitant increase in IFN-y. This in turn
      can induce the expression of PD-L1 in the tumour microenvironment, with subsequent inhibition
      of antitumour T-cell responses, but may also increase the chance of benefit from anti-PD-1
      and anti-PD-L1 therapies. A combination treatment with anti-CTLA-4 (e.g. ipili-mumab) plus
      anti PD-1 (e.g. nivolumab) or anti-PD-L1 antibodies should enable the creation of an
      immunogenic tumour microenvironment with subsequent clinical benefit for patients.

      Nivolumab monotherapy has been approved for the treatment of advanced melanoma (FDA, EMA, and
      Japan) and previously treated squamous NSCLC (FDA, positive CHMP opin-ion). Nivolumab and
      ipilimumab improved PFS compared to nivolumab or ipilimumab alone in a study in melanoma
      (CA209067).

      In a randomised open-label phase I/II trial (CheckMate 032), evaluating nivolumab with or
      without ipilimumab in pretreated SCLC patients with progressive disease and sensitive or
      refractory to platinum based chemotherapy, based on an interim analysis a response rate of
      33% and disease stabilisation in 22% was observed for the combination of nivolumab and
      ipilimumab compared to 18% response rate and 20% stable disease with nivolumab mono-therapy.

      Both, nivolumab monotherapy and nivolumab plus ipilimumab combination treatment were
      tolerable for the treatment of SCLC, and no new safety profile was identified compared to the
      profile of nivolumab with or without ipilimumab in other anti-cancer therapies.

      Nivolumab plus ipilimumab will be administered as a consolidation treatment after comple-tion
      of a standard treatment including chemo-radiotherapy and prophylactic cranial irradia-tion
      (PCI).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2014</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomisation until death from any cause, assessed up to a maximum of 6,5 years</time_frame>
    <description>Defined as time from the date of randomisation until death from any cause. Censoring will occur at the last follow-up date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival determined by RECIST 1.1</measure>
    <time_frame>From date of randomisation until documented progression or death, if progression is not documented, assessed up to a maximum of 6,5 years</time_frame>
    <description>Defined as time from the date of randomisation until documented progression or death, if progression is not documented. Censoring will occur at the last tumor assessment only if patient is lost to follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>From randomisation to termination of trial treatment, up to a maximum of 2 years</time_frame>
    <description>Objective response is defined as best overall response (CR or PR) across all assessment time-points during the period from randomisation to termination of trial treatment.
Objective response to chemo-radiotherapy will be determined by tumour assessment around week 15.
Objective response to trial treatment will be determined using RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>From date of randomisation until discontinuation of treatment for any reason, assessed up to a maximum of 6.5 years</time_frame>
    <description>Defined as time from the date of randomisation to discontinuation of treatment for any reason (including progression of disease, treatment toxicity, refusal and death). Censoring will occur at the last follow-up date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Up to a maximum of 6.5 years</time_frame>
    <description>Adverse events classified according to NCI CTCAE version 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Limited Stage Small Cell Lung Cancer</condition>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Induction: Nivolumab at a dose of 1 mg/kg i.v. followed (on the same day) by Ipilimumab at a dose of 3 mg/kg i.v. once every 3 weeks, 4 cycles
- Maintenance: Nivolumab 240 mg i.v. once every 2 weeks, for a maximum of 12 months from start of maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no further treatment; tumour assessment, follow-up documentation and collection of biological material will be done according to the same schedule as Arm 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)</description>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).</description>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for enrolment:

          -  Histologically or cytologically confirmed small cell lung carcinoma

          -  Untreated limited stage disease ((with the exception of one cycle of chemotherapy
             given prior to enrolment) as defined by stage I-IIIB based on 7th TNM classification
             (IASLC classification for SCLC proposal). M0 proven by

          -  Whole body FDG-PET CT including a contrast-enhanced CT of thorax and upper abdomen
             (incl. liver, kidney, adrenals); OR contrast-enhanced CT of thorax and upper abdomen
             (incl. liver, kidney, adrenals) and bone scan; AND

          -  brain MRI (or contrast enhanced CT of the brain). . within 28 days before start of
             chemotherapy.

          -  Age ≥ 18 years

          -  ECOG performance status 0-1

          -  Adequate haematological function:

          -  haemoglobin &gt; 9 g/dL

          -  neutrophils count &gt;1.5×109/L

          -  platelet count &gt; 100 × 109/L

          -  Adequate liver function:

          -  Total bilirubin &lt; 2.5 × ULN

          -  ALT and/or AST &lt; 2.5 × ULN

          -  alkaline phosphatase &lt; 5 ULN.

          -  Adequate renal function: Calculated creatinine clearance ≥ 30 mL/min (Cockroft-Gault)

          -  Pulmonary function FEV1 of 1.0L or &gt; 40% predicted value and DLCO &gt; 40% predicted
             value.

          -  Patient capable of proper therapeutic compliance, and accessible for correct
             follow-up.

          -  Women of childbearing potential, including women who had their last menstrual period
             in the last 2 years, must have a negative serum or urine pregnancy test within 7 days
             before beginning of chemotherapy.

          -  All sexually active men and women of childbearing potential must use an effective
             contraceptive method (two barrier methods or a barrier method plus a hormonal method)
             during the study treatment and for a period of at least 12 months following the last
             administration of trial drugs.

          -  Measurable or evaluable disease (according to RECIST 1.1 criteria). Not eligible:
             patients with only one measurable or evaluable tumour lesion which was resected or
             irradiated prior to enrolment.

          -  Written Informed Consent (IC) must be signed and dated by the patient and the
             investigator prior to any trial-related intervention for

               1. Chemo-radiotherapy treatment and PCI, and subsequent randomisation, including
                  mandatory biological samples

               2. Optional biological material collection, long-term storage and future use of
                  biological material for translational research

        Inclusion Criteria for randomisation:

          -  Chemo-radiotherapy completed per protocol: 4 cycles of chemotherapy, ≥85% of PTV of
             thoracic radiotherapy, as well as completed, mandatory PCI

          -  non-PD after chemo-radiotherapy and PCI

          -  ECOG performance status 0-2

          -  Recovery of all adverse events to a grade ≤1, except for fatigue, appetite,
             oesophagitis and renal impairment (where ≤2 is allowed) and alopecia (any grade)

          -  Women of childbearing potential, including women who had their last menstrual period
             in the last 2 years, must have a negative serum or urine pregnancy test within 7 days
             before randomisation.

        Exclusion Criteria for enrolment:

          -  Patient with mixed small-cell and non-small-cell histologic features

          -  Patient with pleural or pericardial effusions proven to be malignant

          -  Patients who have had in the past 5 years any previous or concomitant malignancy
             EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ
             carcinoma of the cervix or bladder, in situ ductal carcinoma of the breast (if no RT
             was involved).

          -  Patients with other serious diseases or clinical conditions, including but not limited
             to uncontrolled active infection and any other serious underlying medical processes
             that could affect the patient's capacity to participate in the study.

          -  Ongoing clinically serious infections requiring systemic antibiotic or antiviral,
             antimicrobial, antifungal therapy.

          -  Known or suspected hypersensitivity to nivolumab or ipilimumab or any of their
             excipients.

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results.

          -  Documented history of severe autoimmune or immune mediated symptomatic disease that
             required prolonged (more than 2 months) systemic immunosuppressive (e.g. steroids)
             treatment, such as but not limited to ulcerative colitis and Crohn´s disease,
             rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus
             erythematosus, or autoimmune vasculitis (eg, Wegener's granulomatosis).

          -  Subjects with an autoimmune paraneoplastic syndrome requiring concurrent
             immunosuppressive treatment.

          -  Interstitial lung disease or pulmonary fibrosis

          -  Women who are pregnant or in the period of lactation.

          -  Sexually active men and women of childbearing potential who are not willing to use an
             effective contraceptive method during the study.

          -  Patients with any concurrent anticancer systemic therapy (except for chemotherapy
             cycle 1).

          -  HIV, active Hepatitis B or Hepatitis C infection

          -  Previous radiotherapy to the thorax (prior to inclusion), including RT for breast
             cancer

          -  Planned radiotherapy to lung of mean dose &gt; 20 Gy or V20 &gt; 35 %

          -  Patients who received treatment with an investigational drug agent during the 3 weeks
             before enrolment in the study.

          -  Prior chemotherapy or radiotherapy for SCLC. Exception: one cycle of chemotherapy (as
             specified to section 10.2) may be administered prior to enrolment.

        Exclusion criteria for randomisation:

          -  Less than 4 cycles of chemotherapy administered, less than 85% PTV of thoracic
             radiotherapy delivered, or PCI not completed

          -  Progressive disease after chemo-radiotherapy and PCI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Solange Peters, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>European Thoracic Oncology Platform (ETOP)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk De Ruysscher, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Maastro Clinic, Maastricht, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Ruepp</last_name>
    <phone>+41 31 389 93 91</phone>
    <email>STIMULI@etop-eu.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg, KU Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kristiaan Nackaerts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avignon - Institut Sainte-Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hilgers Werner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caen - Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Radj Gervais</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gérard Zalcman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Percy/Armées</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hervé Le Floch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Merle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Créteil - CHI</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabelle Monnet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Denis Moro-Sibilot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Général</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Molinier, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Girard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyon - Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre-Jean Souquet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabrice Barlesi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Louis Pujol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Didier Debieuvre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRLCC</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaafar Bennouna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nice - CRLCC</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michel Poudenx</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orléans - CH</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adrien Dixmier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris - Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gérard Zalcman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris - Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Damien Pouessel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris - Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacques Cadranel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hervé Lena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth Quoix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suresnes</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sylvie Friard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Clarisse Audigier-Valette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julien Mazieres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Pichon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cécile Le Péchoux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Faehling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LungenClinic Grosshansdorf GmbH</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Reck, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum München-Bogenhausen</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Schütz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoracic Oncology Centre Munich</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rudolf M Huber, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pius-Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frank Griesinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Heinz Kirchen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frank Heinzelmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VUMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joop de Langen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dirk De Ruysscher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bartomeu Massutí</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Barakaldo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guillermo López Vivanco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Margarita Majem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Luis González Larriba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mariano Provencio Pulla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Santiago Ponce Aix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manuel Domine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central De Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neomi Villanueva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen De La Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Irigoyen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario De Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amelia Insa Mollá</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Solange Peters, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandra Curioni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James' University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin Franks, MD</last_name>
      <email>kevin.franks@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Kevin Franks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Popat, Prof.</last_name>
      <email>sanjay.popat@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sanjay Popat, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Califano, MD</last_name>
      <email>raffaele.califano@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Raffaele Califano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Poland</country>
  </removed_countries>
  <link>
    <url>http://www.etop-eu.org/</url>
    <description>Sponsor</description>
  </link>
  <reference>
    <citation>Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012 Jun 10;30(17):2046-54. doi: 10.1200/JCO.2011.38.4032. Epub 2012 Apr 30. Erratum in: J Clin Oncol. 2012 Oct 10;30(29):3654.</citation>
    <PMID>22547592</PMID>
  </reference>
  <reference>
    <citation>Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013 Jan;24(1):75-83. doi: 10.1093/annonc/mds213. Epub 2012 Aug 2.</citation>
    <PMID>22858559</PMID>
  </reference>
  <reference>
    <citation>Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012 May;13(5):459-65. doi: 10.1016/S1470-2045(12)70090-6. Epub 2012 Mar 27.</citation>
    <PMID>22456429</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCLC</keyword>
  <keyword>CTLA-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

